[go: up one dir, main page]

TNSN05044A1 - Use of ikappab kinase inhibitors for the treatment of pain - Google Patents

Use of ikappab kinase inhibitors for the treatment of pain

Info

Publication number
TNSN05044A1
TNSN05044A1 TNP2005000044A TNSN05044A TNSN05044A1 TN SN05044 A1 TNSN05044 A1 TN SN05044A1 TN P2005000044 A TNP2005000044 A TN P2005000044A TN SN05044 A TNSN05044 A TN SN05044A TN SN05044 A1 TNSN05044 A1 TN SN05044A1
Authority
TN
Tunisia
Prior art keywords
pain
treatment
kinase inhibitors
ikappab kinase
ikappab
Prior art date
Application number
TNP2005000044A
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TNSN05044A1 publication Critical patent/TNSN05044A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

THE INVENTION RELATES TO THE USE OF IKB KINASE INHIBITORS THAT ARE SUITABLE FOR PRODUCING MEDICAMENTS FOR THE TREATMENT OF PAIN. SUITABLE INHIBITORS ARE PRODUCED FROM COMPOUNDS OF FORMULAS (I) AND (IA).
TNP2005000044A 2002-08-17 2005-02-16 Use of ikappab kinase inhibitors for the treatment of pain TNSN05044A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (en) 2002-08-17 2002-08-17 Use of IKappaB kinase inhibitors in pain therapy
PCT/EP2003/008628 WO2004022057A1 (en) 2002-08-17 2003-08-05 USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN

Publications (1)

Publication Number Publication Date
TNSN05044A1 true TNSN05044A1 (en) 2007-05-14

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000044A TNSN05044A1 (en) 2002-08-17 2005-02-16 Use of ikappab kinase inhibitors for the treatment of pain

Country Status (34)

Country Link
EP (1) EP1531819B1 (en)
JP (1) JP4504811B2 (en)
KR (2) KR101119845B1 (en)
CN (1) CN100398107C (en)
AR (1) AR043045A1 (en)
AT (1) ATE418336T1 (en)
AU (1) AU2003271555B2 (en)
BR (1) BR0313555A (en)
CA (1) CA2495455C (en)
CO (1) CO5690585A2 (en)
CR (1) CR7716A (en)
CY (1) CY1108874T1 (en)
DE (2) DE10237723A1 (en)
DK (1) DK1531819T3 (en)
EC (1) ECSP055609A (en)
ES (1) ES2320118T3 (en)
HK (1) HK1079426A1 (en)
HR (1) HRP20050041B1 (en)
IL (1) IL166780A (en)
MA (1) MA27334A1 (en)
MX (1) MXPA05001218A (en)
MY (1) MY138059A (en)
NO (1) NO334309B1 (en)
OA (1) OA12907A (en)
PL (1) PL212356B1 (en)
PT (1) PT1531819E (en)
RS (1) RS51878B (en)
RU (1) RU2320338C2 (en)
SI (1) SI1531819T1 (en)
TN (1) TNSN05044A1 (en)
TW (1) TWI325782B (en)
UA (1) UA80837C2 (en)
WO (1) WO2004022057A1 (en)
ZA (1) ZA200500323B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
MX2007000481A (en) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Methods for treating hepatitis c.
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
DE102005025225A1 (en) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Process for the preparation of 2- (2-amino-pyrimidin-4-yl) -1H-indole-5-carboxylic acid derivatives
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5790440B2 (en) * 2010-12-01 2015-10-07 住友化学株式会社 Pyrimidine compounds and their use for pest control
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2787998T (en) 2011-12-06 2017-01-03 Sanofi Sa Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
RU2687094C2 (en) * 2014-07-03 2019-05-07 Санофи [(s)-1-carbamoyl-2-(phenylpyrimidin-2-ylamino)ethyl]amide 2-(2-methylaminopyrimidin-4-yl)-1h-indole-5-carboxylic acid for use in treating osteoarthritis-related pain
EP3823963A2 (en) 2018-07-16 2021-05-26 Novartis AG Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04813B1 (en) * 1999-06-23 2007-04-16 Aventis Pharma Deutschland Gmbh Substituted Benzimidazoles, Their Preparation and their Use in the Preparation of a Drug for the Prophylaxis and Treatment of Diseases Due to Increased NFkB Activity
DE19951360A1 (en) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
WO2004022057A1 (en) 2004-03-18
IL166780A (en) 2011-11-30
KR20110135428A (en) 2011-12-16
RU2005107419A (en) 2005-08-10
CN1674899A (en) 2005-09-28
AU2003271555B2 (en) 2009-03-26
RS51878B (en) 2012-02-29
CY1108874T1 (en) 2014-07-02
BR0313555A (en) 2005-07-12
IL166780A0 (en) 2006-01-15
EP1531819A1 (en) 2005-05-25
JP2005539053A (en) 2005-12-22
MXPA05001218A (en) 2005-05-16
HK1079426A1 (en) 2006-04-07
SI1531819T1 (en) 2009-06-30
AR043045A1 (en) 2005-07-13
CR7716A (en) 2008-11-25
ECSP055609A (en) 2005-04-18
CA2495455A1 (en) 2004-03-18
JP4504811B2 (en) 2010-07-14
ZA200500323B (en) 2006-02-22
PT1531819E (en) 2009-02-18
PL212356B1 (en) 2012-09-28
EP1531819B1 (en) 2008-12-24
MY138059A (en) 2009-04-30
AU2003271555A1 (en) 2004-03-29
KR20050058339A (en) 2005-06-16
ATE418336T1 (en) 2009-01-15
TWI325782B (en) 2010-06-11
CN100398107C (en) 2008-07-02
HRP20050041A2 (en) 2006-04-30
TW200417370A (en) 2004-09-16
RU2320338C2 (en) 2008-03-27
HRP20050041B1 (en) 2013-07-31
DE50310980D1 (en) 2009-02-05
CO5690585A2 (en) 2006-10-31
OA12907A (en) 2006-10-13
CA2495455C (en) 2011-01-11
RS20050070A (en) 2007-06-04
DK1531819T3 (en) 2009-04-20
NO20051339L (en) 2005-05-03
ES2320118T3 (en) 2009-05-19
PL373568A1 (en) 2005-09-05
UA80837C2 (en) 2007-11-12
MA27334A1 (en) 2005-05-02
KR101119845B1 (en) 2012-02-28
DE10237723A1 (en) 2004-07-08
NO334309B1 (en) 2014-02-03

Similar Documents

Publication Publication Date Title
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
TW200510416A (en) P38 inhibitors and methods of use thereof
AU2004263179A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
MXPA05013075A (en) P-38 inhibitors.
GB0223040D0 (en) Therapeutic compounds
HK1085511A1 (en) Complement inhibitors from ticks
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
EP1567157A4 (en) Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases
GB0112348D0 (en) Compounds
IL173348A (en) Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments
PL1699800T3 (en) Bicyclic heterocyclic p-38 kinase inhibitors
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
MXPA05008438A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands.
MXPA05009885A (en) Novel fused triazolones and the uses thereof.
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MXPA05005314A (en) Novel lapachone compounds and methods of use thereof.
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
YU21404A (en) Substituted benzimidazole compounds and their use for the treatment of cancer
UA83821C2 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
MXPA04005809A (en) Protein kinase inhibitors.